IOncology

Editor's Note: At the 2024 Annual Meeting of the Shanghai Anti-Cancer Association’s Gastrointestinal Tumor Laparoscopy Committee, Dr. Hongwei Yao from Beijing Friendship Hospital，Capital Medical University delivered an outstanding presentation titled…

Renal cancer is a common malignancy of the urinary system. For localized and locally advanced renal cancer without distant or extraregional lymph node metastases, surgical removal of the tumor or the affected kidney remains the primary treatment. Recent advances in targeted therapy and immunotherapy have expanded the options for perioperative treatment of renal cancer. In 2024, this field saw significant breakthroughs, and Dr. Liangyou Gu from the Chinese PLA General Hospital shared the latest research developments.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global experts, scholars, and industry leaders in cellular and immunotherapy.…

Editor’s Note: As precision medicine continues to advance, breakthroughs in immunotherapy and the development of personalized treatment strategies are ushering in an exciting new era for lung cancer treatment. On…

The "Northern Breast Cancer Salon Annual Progress Review" was held in Beijing from January 3 to 5, 2025, providing a comprehensive overview of the latest developments in the diagnosis, treatment, and research of breast cancer over the past year. Dr. Shusen Wang from the Sun Yat-sen University Cancer Center presented a summary of the advances in endocrine therapy for advanced breast cancer in 2024. After the conference, Oncology Frontier invited Professor Wang for an in-depth interpretation of these significant developments.

In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens, and comprehensive perioperative management. As the year comes to an end, Oncology Frontier invited Dr. Changli Wang from Tianjin Medical University Cancer Institute and Hospital to review the progress and discuss the future prospects of perioperative immunotherapy for NSCLC in 2024.

As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year's advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.

Editor’s Note: With the discovery of lung cancer driver genes and the rapid development of drug research, targeted therapy for advanced non-small cell lung cancer (NSCLC) has made significant progress,…

Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery ineffective. Currently, effective and cost-efficient screening tools for the general population are lacking, and recommended screening strategies, like cross-sectional imaging and endoscopic ultrasonography, are limited to high-risk individuals.